Investor Presentation
Filed with ASX · · 23 pages · English
Summary by 6ix AI
Acrux Limited has released an updated investor presentation following the FDA approval of Nitroglycerin Ointment and the announcement of a share placement to raise funds from institutional investors. Additionally, it details the company's leadership team and its capabilities in the specialty pharmaceutical sector. The filing also includes information about a capital raise plan to secure further funding for product development and market expansion.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Acrux
- Share Placement successfully concluded and SPP launched
- FDA Approval - Nitroglycerin Ointment
- Trading Halt
- AGM Presentation
- FY24 R&D Tax Incentive rebate received
Later from Acrux
- Share Purchase Plan Offer Booklet
- Commercialisation of Nitroglycerin Ointment
- Investor Deck update, SPP Closes 18 December 2024, 5pm
- Acrux raises $1.34 million from SPP
- Launch of 90 gram pack size of Dapsone 5%, Gel in US
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux